Small-molecule Drug Development: Selecting And Working With Contract Manufacturing Organizations (CMOs). James M. Hamby, R.Ph., Ph.D. Director of Business.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

Program Management Office (PMO) Design
PROJECT TITLE Project Leader: Team: Executive Project Sponsor (As Required): Date: Month/Day/Year 110/17/2014 V1.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
Chapter 3 Project Initiation
Batch Reworking and Reprocessing
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
Financial Systems Needs Assessment Project Update Monthly Research Administrators Meeting March 11, 2010.
Establishing Preclinical Development Operations in China Ming Guo, Ph.D. VP Pharmaceutical Sciences & Manufacturing SABPA Pacific Forum Nov. 4, 2006.
1 2-1 McGraw-Hill/Irwin Copyright © 2003 by The McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin © 2003 The McGraw-Hill Companies, Inc.,
Consulting for Life Sciences 1 Confidential October 14, 2014 Strategic Science and Technology Capabilities Discussion
Chapter 3 Project Initiation. The stages of a project  Project concept  Project proposal request  Project proposal  Project green light  Project.
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
VALIDATION OF RAW MATERIALS
What are MRLs ? Alfred W. Clark Dawnbreaker, Inc.
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
Custom Synthesis (R&D and cGMP)| Commercialization Expertise |Consulting Services.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
A SOUND INVESTMENT IN SUCCESSFUL VR OUTCOMES FINANCIAL MANAGEMENT FINANCIAL MANAGEMENT.
World Health Organization
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Technology Transfer & Quality
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
© 2008 Stephen M Pondell Innovative Strategies for Effectively Working with a CMO When Cost is Not a Motivator A Virtual Company Perspective Steve Pondell.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
PRODUCT TRANSFER.
Product Development Chapter 6. Definitions needed: Verification: The process of evaluating compliance to regulations, standards, or specifications.
© 2006 Cisco Systems, Inc. All rights reserved.Cisco Public 1 Version 4.0 Gathering Network Requirements Designing and Supporting Computer Networks – Chapter.
Best Strategies for a Small Company Dealing with CMOs: What to do when Money is NOT a Motivator Steve Pondell 29 Nov, 2006.
Product Documentation Chapter 5. Required Medical Device Documentation  Business proposal  Product specification  Design specification  Software.
Important informations
Establishing the Supply Chain A Small Company Perspective Biomedical Technology Club March 7, 2006.
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Copyright © 2013 Pearson Education, Inc. Publishing as Prentice Hall o P.I.I.M.T o American University of Leadership Ahmed Hanane, MBA, Eng, CMA, Partner.
Challenges of a First Commercial Product Launch Steve Pondell January 8, 2008.
© 2006 Cisco Systems, Inc. All rights reserved.Cisco Public 1 Version 4.0 Gathering Network Requirements Designing and Supporting Computer Networks – Chapter.
Overview of FDA's Regulatory Framework for PET Drugs
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
Molecule-to-Market-Place Quality
Validation Copyright © 2004 Yokogawa Validation. Copyright © 2004 Yokogawa Page 2 Validation ProjectStandard Project > Validation.
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
ISPE Central Canada Chapter Annual Meeting September 28, 2006 Yvon R. Tessier Pharmaceutical contract manufacturing challenges.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Draft Guidance for Industry: CGMPs for Phase 1 INDs Joseph C. Famulare, Director Division of Manufacturing & Product Quality Office of Compliance, CDER,
PUBLIC–PRIVATE PARTNERSHIP (PPP) FRAMEWORK AND GUIDELINES Syed M. Ali Zaidi, P.Eng. PM(Stanford), Ph.D. Director, Strategic Partnerships Alberta Infrastructure.
1 A Seminar On Pharmaceutical Outsourcing A Seminar On Pharmaceutical Outsourcing.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
R. Hoffman March 2009 Company Confidential Copyright © 2000 Eli Lilly and Company 1 Extemporaneous Preparation (EP) of Clinical Trial Materials for Phase.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
W w w. g a l c h i m i a. c o m The leading Medchem service provider in Spain.
New Light Path TM Services. slide 2 Light Path TM : streamlined custom material supply for discovery to early development n Leverage Lonza’s proven technology.
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Regulatory Intelligence for the Emerging Markets Lisa Rysso-DeMaggio President, RAQUELIAN Consulting DIA Regulatory Intelligence Working Group, 10 Sep.
נמטוציטים משושנת ים Eli. S Lec. No.2.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Systems Analysis and Design in a Changing World, 4th Edition
CTD Content Management
Lesson 5: BRITE Seminar: GMP II
Quality System.
Request for Proposal & Proposal
Presentation transcript:

Small-molecule Drug Development: Selecting And Working With Contract Manufacturing Organizations (CMOs). James M. Hamby, R.Ph., Ph.D. Director of Business Development Ash Stevens, Inc Krause Street Riverview, MI Tel: (734) ext Web:

Ash Stevens Inc.: an Established, Stable API Contractor  Early-Stage Development Through Commercial Manufacturing Of APIs  Eleven FDA Approved Commercial APIs: Velcade (5/03), Vidaza (5/04), and Clolar (12/04)  cGMP Compliant Operations  Provider Of Contract Research Services To The Federal Government (NIH &NCI)  Dun and Bradstreet Rating of “4A1”

Chemistry Milestones for an NDA NDA Filing Validatable Process One Batch Prior To Filing Development Report Impurities Identified 12 Months Stability – 3 Batches (API Shipping and Storage Only) FDA PAI One Validation Batch Complete Protocol for Two Additional Batches Approval to Market Phase II/III Parametric Studies Validated Analytical Methods; Starting Material, Intermediate, and Product Specifications; Packaging Phase I “Manageable” Process Process Hazard Review Cleaning Procedures Scientifically Sound Analytical Methods Development Candidate Stability Program Stability Studies Including Three Lots of API Mfg. Batch Definition Unit Operations Scale of Batch

cGMP Compliance  ICH Guidelines And US 21 CFR Regulations Mandate That The Sponsor Company Is Responsible For Assuring Compliance With cGMP Regulations  Therefore, It Is Incumbent Upon The Sponsor To Ensure That Third Party Generated Data Is Of The Highest Quality And That The Sponsor Can Defend The Integrity Of The Data And The Process

Managing Drug Development  Ideal Situation Is to Have An In-House Drug Development Team Experienced At Working With CMOs  CMC Consultants And CRO’s  Experienced CMO (Turnkey)

Key Steps In Identifying A CMO  Due Diligence-Identifying Potential CMO Partners  Preparing the Technical Package (RFPs)  Evaluating the Proposal  Site Visit  Quality Systems Audit

Due Diligence-Identifying A CMO Partner

 Provide Enough Time To Do Thorough Due Diligence  Avoid “I Need It Yesterday” And Unrealistic Expectations  Understand Your Project the Process, Timelines And Costs  Chemical Manufacturing Tradeshows (InformEx, ChemOutsourcing)  Rep Visits Due Diligence

 Good Fit For Project Needs And Strategy  Capacities And Capabilities  Reputation For Quality And Delivering On Time and On Budget (# Of NCE API Approvals, References)  Regulatory Inspection History  Financial Stability  Location And Accessibility Due Diligence

The Request For Proposal (RFP) Technical Package

The Request For Proposal (RFP):  CDA In Place  Share All Pertinent Information (Better Quality Quote)  Provide Full Experimental Details And Yields  Clearly Communicate Required Deliverables, Quantities, And Timelines

The Request For Proposal (RFP):  Describe Intended Use Of Material (e.g. 500g For GLP Tox. And 3 Kg cGMP For Phase I Studies)  Define General Purity Specifications For Deliverables (e.g. >95% Pure For GLP Tox. Material)

Proposal/Quote Assessment

 Comments And Strategy Section  All Costs and Work Clearly Defined  Risk-Based Proposals  Start Date  Intellectual Property

Early-Stage Project: Initial Tasks 1. Process Feasibility and Evaluation 2. Preliminary Process Development 3. Demonstration Batch ( g, non- GMP) 4. Initial Phase I GMP Batch (1-5 Kg) 5. Analytical Development

CMO: Site Visit

 Meet “Key” People, Explain Expectations And Requirements, Timelines (A Team Vs. B Team)  Project Manager Key Person  Communication & Resolution Of Problems  EHS&S, Housekeeping & Cleanliness  Tech Transfer: Scale-up From Grams To Kilograms, non-GMP vs. GMP  Hours Of Operation And Vacation Schedules  Quality Systems (Audit?) CMO Site Visit

 Modern Equipment And Facility, But Be Conscious Of The Wow Factor  Confidentiality: Chemical Structures Written on Hoods or Glassware, Client Names Or Client Compound Numbers Visible, Numbers Written On Hand or Scraps Of Paper,  How Busy Is The CMO, Are They Flexible  How Much Does the CMO Value Your Business (Win/Win) CMO Site Visit

Early-Stage Strategy: Proof Of Concept ASAP And Exit/Partner

Early-Stage Development Project  Developing An In-licensed Drug Or A Drug From In-house Discovery Effort  Discovery Route: Milligrams To A Few Grams  Strategy: Proof Of Concept; Find A Development Partner Or Sell Company  1-5 Kg GMP Required For Phase 1-2b (IND Path)  Partner: Approval ASAP And Commercialize (NDA Path)

Early-Stage Development Project  Sponsor Strategy: Hammer Out GMP API By The Discovery Route To Save Time And Money.  Often A Risky Strategy  Rarely Is The Discovery Route Amenable To GMP Scale-up  High Probability Of Encountering Chemistry Issues

Early-Stage Development Project  Partner May Need To Reinvent The Process For Plant Scale Production  The Lack Of A Robust GMP Process Can Effect The Value Of A Deal  An Experienced CMO Can Help The Sponsor Optimize The Their Strategy

The Challenge Time/ Reliability Quality Cost

Comprehensive Medicinal Chemistry Vol. II (Strategy And Drug Research) Vol. Editor Walter Moos, Publisher Elsevier, Chapter 2.05, Pages “The Role of the Chemical Development, Quality, and Regulatory Affairs Team in Turning a Potent Agent into a Registered Product” Stephen A. Munk, Ph.D. Ash Stevens Inc., Detroit, MI